Non-steroidal anti-inflammatory drugs and venous thromboembolism in women

Pharmacoepidemiology and Drug Safety

Volumn 22, Issue 6, 2013, Pages 658-666

  Bergendal, Annica ^a   Adami, Johanna ^a   Bahmanyar, Shahram ^a   Hedenmalm, Karin ^b,c   Lärfars, Gerd ^d   Persson, Ingemar ^a,b   Sundström, Anders ^a   Kieler, Helle ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b MEDICAL PRODUCTS AGENCY   (Sweden)

^c UPPSALA UNIVERSITY   (Sweden)

^d STOCKHOLM SÖDER HOSPITAL   (Sweden)

Author keywords

Case control study; Epidemiology; Non steroidal anti inflammatory drugs; Pharmacoepidemiology; Venous thromboembolism; Women

Indexed keywords

BLOOD CLOTTING FACTOR 5 LEIDEN; CELECOXIB; DEXIBUPROFEN; DICLOFENAC; ETORICOXIB; IBUPROFEN; INDOMETACIN; KETOPROFEN; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PROTHROMBIN; ROFECOXIB; SULINDAC; VALDECOXIB;

ADULT; ANTICOAGULANT THERAPY; ARTICLE; BODY MASS; CASE CONTROL STUDY; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG USE; FEMALE; GENE MUTATION; HORMONAL CONTRACEPTION; HORMONAL THERAPY; HUMAN; IMMOBILIZATION; PRIORITY JOURNAL; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING; VENOUS THROMBOEMBOLISM;

ADOLESCENT; ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BODY MASS INDEX; CASE-CONTROL STUDIES; FEMALE; HUMANS; INCIDENCE; LOGISTIC MODELS; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; REGISTRIES; SWEDEN; VENOUS THROMBOEMBOLISM; YOUNG ADULT;

EID: 84878771664     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.3436     Document Type: Article

References (24)

1. Rosendaal FR. Venous thrombosis: a multicausal disease. Lancet 1999 Apr 3; 353(9159): 1167-73.
2. Grady D, Wenger NK, Herrington D, et al. Postmenopausal hormone therapy increases risk for venous thromboembolic disease. The Heart and Estrogen/progestin Replacement Study. Ann Intern Med 2000; 132(9): 689-96.
3. Rosendaal FR, Van Hylckama Vlieg A, Tanis BC, Helmerhorst FM. Estrogens, progestogens and thrombosis. J Thromb Haemost 2003; 1(7): 1371-80.
4. Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000; 343(21): 1520-8, 2 p following 8.
5. Kearney PM, Baigent C, Godwin J, Halls H, Emberson JR, Patrono C. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ. [Comparative Study Meta-Analysis Research Support, Non-U.S. Gov't]. 2006; 332(7553): 1302-8.
6. McGettigan P, Henry D. Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. JAMA [Meta-Analysis Research Support, Non-U.S. Gov't Review]. 2006; 296(13):1633-44.
7. Franchini M, Mannucci PM. Venous and arterial thrombosis: different sides of the same coin? Eur J Intern Med [Review]. 2008; 19(7): 476-81.
8. Schmidt M, Christiansen CF, Horvath-Puho E, Glynn RJ, Rothman KJ, Sorensen HT. Non-steroidal anti-inflammatory drug use and risk of venous thromboembolism. JTH [Research Support, Non-U.S. Gov't]. 2011; 9(7): 1326-33.
9. Huerta C, Johansson S, Wallander MA, Garcia Rodriguez LA. Risk factors and short-term mortality of venous thromboembolism diagnosed in the primary care setting in the United Kingdom. Arch Intern Med [Research Support, Non-U.S. Gov't]. 2007; 167(9): 935-43.
10. Tsai AW, Cushman M, Rosamond WD, Heckbert SR, Polak JF, Folsom AR. Cardiovascular risk factors and venous thromboembolism incidence: the longitudinal investigation of thromboembolism etiology. Arch Intern Med 2002; 162(10): 1182-9.
11. Lacut K, van der Maaten J, Le Gal G, Cornily G, Mottier D, Oger E. Antiplatelet drugs and risk of venous thromboembolism: results from the EDITH case-control study. Haematologica [Letter Research Support, Non-U.S. Gov't]. 2008; 93(7): 1117-8.
12. Biere-Rafi S, Di Nisio M, Gerdes V, et al. Non-steroidal anti-inflammatory drugs and risk of pulmonary embolism. Pharmacoepidemiol Drug Saf 2011; 20(6): 635-42.
13. Sundstrom A, Seaman H, Kieler H, Alfredsson L. The risk of venous thromboembolism associated with the use of tranexamic acid and other drugs used to treat menorrhagia: a case-control study using the General Practice Research Database. BJOG 2009; 116(1): 91-7.
14. Bergendal A, Bremme K, Hedenmalm K, et al. Risk factors for venous thromboembolism in pre-and postmenopausal women. Thromb Res 2012; 130(4): 596-601.
15. Roumie CL, Mitchel EF, Jr., Kaltenbach L, Arbogast PG, Gideon P, Griffin MR. Nonaspirin NSAIDs, cyclooxygenase 2 inhibitors, and the risk for stroke. Stroke [Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S.]. 2008; 39(7): 2037-45.
16. Johnson AG, Day RO. The problems and pitfalls of NSAID therapy in the elderly (Part II). Drugs & aging [Review]. 1991; 1(3): 212-27.
17. Pilotto A, Franceschi M, Leandro G, Di Mario F. NSAID and aspirin use by the elderly in general practice: effect on gastrointestinal symptoms and therapies. Drugs Aging [Research Support, Non-U.S. Gov't]. 2003; 20(9): 701-10.
18. Graff J, Skarke C, Klinkhardt U, et al. Effects of selective COX-2 inhibition on prostanoids and platelet physiology in young healthy volunteers. JTH [Randomized Controlled Trial Research Support, Non-U.S. Gov't]. 2007; 5(12): 2376-85.
19. Rabausch K, Bretschneider E, Sarbia M, et al. Regulation of thrombomodulin expression in human vascular smooth muscle cells by COX-2-derived prostaglandins. Circ Res [Comparative Study Research Support, Non-U.S. Gov't]. 2005; 96(1): e1-6.
20. Bishop-Bailey D, Pepper JR, Larkin SW, Mitchell JA. Differential induction of cyclooxygenase-2 in human arterial and venous smooth muscle: role of endogenous prostanoids. Arterioscler Thromb Vasc Biol [Research Support, Non-U.S. Gov't]. 1998; 18(10): 1655-61.
21. Catella-Lawson F, Crofford LJ. Cyclooxygenase inhibition and thrombogenicity. Am J Med [Review]. 2001; 110(Suppl 3A): 28S-32S.
22. Armstrong PC, Kirkby NS, Zain ZN, Emerson M, Mitchell JA, Warner TD. Thrombosis is reduced by inhibition of COX-1, but unaffected by inhibition of COX-2, in an acute model of platelet activation in the mouse. PLoS One [Research Support, Non-U.S. Gov't]. 2011; 6(5): e20062.
23. Riman T, Dickman PW, Nilsson S, et al. Hormone replacement therapy and the risk of invasive epithelial ovarian cancer in Swedish women. J Natl Cancer Inst 2002; 94(7): 497-504.
24. Blomgren KB, Sundstrom A, Steineck G, Genell S, Sjostedt S, Wiholm BE. A Swedish case-control network for studies of drug-induced morbidity--acute pancreatitis. Eur J Clin Pharmacol 2002; 58(4): 275-83.